Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of High-Fat Meal on Bexagliflozin PK in Healthy Subjects
NCT02820298Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time of Maximum Observed Plasma Concentration and 3 more. Started Jun 2016; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02820298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820298.